Compare JOE & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | XENE |
|---|---|---|
| Founded | 1936 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.2B |
| IPO Year | 2002 | 2014 |
| Metric | JOE | XENE |
|---|---|---|
| Price | $70.96 | $59.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $67.25 |
| AVG Volume (30 Days) | 154.6K | ★ 1.2M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 56.69 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $513,246,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,823.63 |
| P/E Ratio | $35.36 | ★ N/A |
| Revenue Growth | ★ 27.44 | N/A |
| 52 Week Low | $40.19 | $26.74 |
| 52 Week High | $73.54 | $62.91 |
| Indicator | JOE | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 75.34 |
| Support Level | $65.30 | $37.91 |
| Resistance Level | $72.72 | N/A |
| Average True Range (ATR) | 2.69 | 2.13 |
| MACD | -0.31 | 1.93 |
| Stochastic Oscillator | 66.27 | 84.43 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.